IFPA

World Psoriasis Day 2023: Let’s Unite for Action

Vanco Vlastimil (��ֳ� S.A.) — Fri, 27 Oct 2023 10:51:16 +0000

World Psoriasis Day 2023: Let’s Unite for Action

Rajesh Gupta, Patient Value Immunology & US Solutions

Vanco Vlastimi… Fri 27/10/2023 - 12:51

On October 29th, World Psoriasis Day, ��ֳ� will proudly unite with the International Federation of Psoriasis Associations (IFPA) and the global community to show our support for people living with psoriasis and psoriatic arthritis. This annual awareness day is presented by IFPA and is observed in over 70 countries across the world. The theme for World Psoriasis Day 2023, set by IFPA, is "Access for All” which advocates that everyone living with psoriatic disease has access to quality care regardless of their income or geography.

Psoriasis is a chronic inflammatory skin disease that affects over 125 million people worldwide. An estimated 30% of people living with psoriasis also develop psoriatic arthritis, a progressive inflammatory disease that can cause joint swelling, pain, and stiffness, potentially leading to irreversible joint damage if not properly managed. These diseases are multifaceted with significant physical, emotional and psychological burdens on all aspects of daily life.

At ��ֳ�, we are steadfast in our commitment to enhancing the lives of those living with psoriasis and psoriatic arthritis. We unite a diverse range of perspectives and scientific expertise, fostering collaborations with stakeholders, healthcare providers, and patient organizations to advance solutions. Our collective goal is to dismantle and eliminate the barriers to a better quality of life for individuals living with these diseases.

This World Psoriasis Day and every day, we are proud to stand alongside the global community to work towards our common goal for a healthier and more inclusive future for all those living with psoriasis and psoriatic arthritis. On this day, we take the opportunity to thank the community for their collaboration, dedication and unwavering support to alleviate the burden caused by the challenges and uncertainties of these diseases.

The mission for World Psoriasis Day is multifold. We must continue to raise awareness and help build a wider understanding of these diseases and their impact. This year, join us in uniting for action and showing solidarity to people living with psoriasis and psoriatic arthritis.

Follow our social channels to learn more.

solutions

551 Likes

Advancing Innovation in Dermatology with Collaborative Partnerships

Chiara Vona — Mon, 21 Nov 2022 13:05:19 +0000

Advancing Innovation in Dermatology with Collaborative Partnerships

Emmanuel Caeymaex, Patient Value Immunology & US Solutions

Chiara Vona Mon 21/11/2022 - 14:05

At ��ֳ�, we are committed to improving the lives of those with immune-mediated inflammatory diseases. We embrace the possibility to create a world free from the burden of chronic inflammatory skin diseases – but we can’t do this alone. Guided by our Patient Value Strategy, our purpose is to join forces with community stakeholders to advance high quality scientific research and debate, address unmet patient needs and enhance critical aspects of the patient pathway. That’s why we maintain deep connections with patient and scientific communities to drive innovation and co-create life-changing solutions.

Since 2015, our Patient Value Strategy has been the driver of ��ֳ�’s approach to delivering value for patients. Our operational model puts patients and their individual experiences at the heart of everything we do – from discovery to development to delivery. ��ֳ� has several strategic dermatology partnerships designed to obtain a better scientific understanding of dermatologic conditions, uncover unmet needs, and improve the standard of care for people living with chronic inflammatory dermatological diseases.

IMPROVING SCIENTIFIC UNDERSTANDING OF INFLAMMATORY SKIN DISEASES

As part of our mission to understand inflammatory skin diseases, ��ֳ� is proud to partner on a new EU Research Project—HIPPOCRATES—to improve diagnostic and therapeutic options for people living with psoriasis (PsO) and psoriatic arthritis (PsA). The overall aim of HIPPOCRATES is to promote the earliest possible diagnosis, increase therapeutic options and improve quality of life for people with PsO and PsA. HIPPOCRATES brings together 26 European partners, with involvement of patients, clinicians, primary care practitioners, regulators, small and medium enterprises, and pharmaceutical companies. The team of experts will evaluate and validate newly discovered biomarker signatures for the early diagnosis of PsA, identification of PsO patients at risk of developing PsA, identification of PsA patients at highest risk of damage progression and for personalized or stratified treatment strategies.

Cross-collaboration is critical to improving scientific understanding of inflammatory dermatological diseases and enhance care. In line with this, ��ֳ�’s partnership with IMI BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) aims to identify biomarkers of variation in disease outcomes to address the main unmet needs of people living with atopic dermatitis (AD) and PsO, who often experience high variability in symptoms, disease progression and treatment response. IMI BIOMAP is a partnership that brings together twenty-six academic institutions, five patient organizations and five industry partners to create a pan-EU biospecimen and data resource of high quality, multi-dimensional datasets on skin and blood from more than 50,000 patients. The data resource will be used to examine the causes and mechanisms of these conditions and will be accessible via a central analysis portal. State of the art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling will analyze AD and PsO patient data.

In addition to this, ��ֳ� partners with The Accelerating Medicines Partnership®: Autoimmune and Immune-Mediated Diseases (AMP®-AIM), an initiative from the Foundation for the US National Institutes of Health (FNIH) to dissect unique disease-centric pathways for psoriatic spectrum disease and several other systemic autoimmune disorders. AMP®-AIM will advance scientific understanding of key disease pathways using new tools to map how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury. The resulting data will accelerate our understanding of the fundamental mechanisms and causes of autoimmune disease, allow more informed selection of patients for clinical trials and generate new targets for drug development.

��ֳ� is also part of Psorcast, a new non-profit, pre-competitive research study developed by the Digital Biomarker Consortium. Psorcast’s objective is to collect and validate patient generated smartphone-based longitudinal measurements of psoriatic disease digital biomarkers that complement clinical measures and monitor psoriatic disease outside of clinical visits. The Psorcast app allows patients with PsO and PsA to measure and monitor changes in their skin and joints over time. The Digital Biomarker Consortium includes Sage Bionetworks, the Psoriasis and Psoriatic Arthritis Clinics Multi-Center Advancement Network, and several other pharmaceutical companies. Helping to improve PsO and PsA diagnosis, understand their disease pathways and improve monitoring and measurement through these partnerships is just the beginning for us, as we continually strive to create value at every stage of the patient journey.

UNCOVERING UNMET NEEDS

To uncover unmet needs for people living with chronic inflammatory skin diseases, ��ֳ� partners with the International Federation of Psoriatic Disease Associations (IFPA), a pivotal international patient advocacy organization that unites, strengthens, and leads the global psoriatic disease community. Our partnership with IFPA allows us to better understand the unique underserved needs of PsO and PsA patients and support them in addressing the profound impact that psoriatic disease has on their lives, including in work, social activities, relationships and home life.
Furthermore, to help people living with Hidradenitis Suppurativa (HS), ��ֳ� and Stanford University established a multi-year collaboration that, among others, aims to better understand HS sub-populations and at-risk groups. The goal of this is to jointly develop unique solutions that combine clinical, real-world, and other data sets — along with the required expertise — to deliver better patient outcomes. The ��ֳ�-Stanford Digital Health Research Collaborative will enable us to develop a better grasp of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. By understanding the key unmet needs for people living with dermatological diseases ��ֳ� can, more effectively, create solutions that place these needs at the center.

RAISING THE STANDARD OF CARE

As well as improving scientific understanding of inflammatory diseases and identifying the highest unmet needs, we are committed to improving on delivery and raise the standard of care for people living with dermatological diseases. Given this, ��ֳ� has joined a pre-competitive collaboration with AbbVie, Almirall, GSK, Janssen, Leo Pharma, Lilly, Novartis, Pfizer and Sanofi to improve research into digital solutions for AD. The collaboration effort was led and facilitated by the Digital Medicine Society, a global non-profit organization working to broaden the acceptance of digital medicine to enhance public health. The pre-competitive collaboration arose from the common interest of developing a standardized “Nocturnal Scratch Measurement” to overcome these challenges. Following the year-long collaboration, during which ��ֳ� played a highly active role, the team has created a new suite of resources that will allow clinical researchers and drug developers to understand, communicate and deploy digital measurements of nocturnal scratching in AD patients.

Being liberated from the physical, emotional and social burden attached to inflammatory dermatological diseases is still wishful thinking for many patients, despite immense advances in drug development and the advent of novel therapeutics and targeted treatments. Epicensus is a ��ֳ� initiative that will challenge the status quo. For our Epicensus (Consensus and Action to Elevate Psoriasis Care) program, we have engaged a multidisciplinary council of experts—including clinicians, payors, and patient representatives—to gain a holistic understanding of the complex and multi-faceted diagnostic and treatment journey for patients with psoriasis. The goal is to drive action and initiate a paradigm shift to enhance the delivery of future psoriasis care in Europe optimizing outcomes and finally allow people living with psoriasis to experience life to its fullest.
These projects demonstrate what an exciting time it is in the field of dermatology—with science advancing at an incredible rate—and through connecting stakeholders across the research community and health systems we can realize its full potential.

��ֳ�’s ambition is to launch multiple ground-breaking new therapies in dermatology to make disease prevention and cure a reality. While our goals are exciting and ambitious, they can only be achieved through partnership and collaboration, ground-breaking research and the purpose-driven dedication of our ��ֳ� employees. Together, we can transform the lives of patients and evolve the future of dermatology treatment.

about ucb

psoriasis partnerships dermatology innovation Hippocrates Epicensus IFPA science

488 Likes

Uniting with the Community for World Psoriasis Day 2022

Vanco Vlastimil (��ֳ� S.A.) — Thu, 27 Oct 2022 08:40:23 +0000

Uniting with the Community for World Psoriasis Day 2022

Rajesh Gupta, Patient Value Immunology & US Solutions

Vanco Vlastimi… Thu 27/10/2022 - 10:40

Each year on October 29, the global community unites for World Psoriasis Day to raise awareness, spread information and increase knowledge about psoriatic disease. ��ֳ� is proud to support this day, led by the International Federation of Psoriatic Disease Associations (IFPA). Each year, World Psoriasis Day, takes a different theme to highlight the many aspects of this disease, with this year’s focus being on mental health.

Psoriasis and psoriatic arthritis are multifaceted conditions affecting multiple parts of the body, like the skin, joints, or both. People living with these conditions can come at an increased risk of developing co-morbidities such as obesity, diabetes, and cardiovascular disease. Living with these physical symptoms and risks can be debilitating and can cause a significant social and emotional burden, impacting mental health and quality of life. Approximately 125 million people worldwide are living with psoriasis. An estimated 30% of people with psoriasis go on to develop psoriatic arthritis.

Mental health is recognized as an integral part of health and well-being. Raising awareness and educating on the wider impact of psoriasis and psoriatic arthritis can increase understanding and help ease the stigma associated with these conditions. At ��ֳ�, we have a long-term commitment to help improve the lives of people living with psoriasis and psoriatic arthritis. By uniting with the community to address unmet needs, support clinical research and build strong, collaborative advocacy partnerships, we aim to make a meaningful difference.

We look forward to a future where the people living with these conditions can unload the burden caused by the challenges and uncertainties of disease.

solutions

World Psoriasis Day IFPA psoriasis psoriatic arthritis

Comment:

Posted by Leah Howard, JD, 28 October 2022

As CEO of the National Psoriasis Foundation, I want to thank you for highlighting the significant burden of living with psoriatic disease. We share your optimism for the future and invite anyone living with or caring for someone living impacted by psoriasis or psoriatic arthritis to take advantage of NPF's free resources and support at psoriasis.org. Together, we will achieve our vision of a life free of psoriatic disease and their burdens.

359 Likes

Together we can make a difference on World Psoriasis Day

eCMSadmin — Fri, 29 Oct 2021 15:45:00 +0000

Together we can make a difference on World Psoriasis Day

Rajesh Gupta, Patient Value Immunology & US Solutions

eCMSadmin Fri 29/10/2021 - 17:45

As a proud supporter of World Psoriasis Day, ��ֳ� sat down with Frida Dunger Johnsson, Executive Director of the International Federation of Psoriasis Associations (IFPA), to learn more about the importance of World Psoriasis Day and how people can unite on October 29 to show their support.

“Together with our members, we share the vision of a future where all people living with psoriatic disease enjoy good health and wellbeing, free from stigma and preventable disability and comorbidities,” explains Frida. Reflecting further on IFPA’s mission, Frida confirms it is to “unite, strengthen and lead the global community to improve the lives of all people affected.” Each year on World Psoriasis Day the global community follows IFPA in this mission, coming together to raise awareness and call for action in support of people living with psoriatic disease.

As the only global organization representing and uniting all people living with psoriatic disease, IFPA continuously works to highlight unmet needs, and recently formulated five strategic goals to generate and share evidence to inform change.

According to Frida the most prominent unmet needs faced by patients with psoriatic disease relate to:

Early diagnosis of psoriatic disease
Equal access to treatment, specialists and individualized care
Training for healthcare practitioners to ensure adequate understanding of the physical, emotional, economic and social burden of the disease, as well as the impact on an individual’s quality of life
Multidisciplinary care to identify and manage common comorbidities
Awareness of stigmatization and discrimination.

Raising awareness is an important step towards combatting these challenges and making a meaningful difference to peoples’ lives. “We aim to make the world aware of psoriatic disease and the effect it has on an individual’s life, spread information and dispel common misconceptions,” Frida added.

In line with this year’s theme for World Psoriasis Day, ‘United’, IFPA is uniting individuals, organizations and IFPA partners from all countries and backgrounds to speak out from a common platform. In doing so, it hopes to empower ministers, governments, and decision-makers to step up their efforts to provide better access to treatment and care for people living with psoriatic disease. “World Psoriasis Day is a powerful opportunity to mobilize advocacy and stand united with the global community to unleash loud action and achieve targeted breakthroughs,” Frida remarked.

There are many ways to support IFPA’s initiatives on World Psoriasis Day, whether you are affected by psoriatic disease or not. Supporters can visit psoriasisday.org to add details of planned World Psoriasis Day activities to the global map, create their own World Psoriasis Day graphics using IFPA’s image generator, find out about the IFPA World Psoriasis Day Petition or simply interact on social media and join the conversation using #WorldPsoriasisDay. Frida concludes, “Any action you take brings us closer to our vision and, together, we can drive positive change for people living with psoriatic disease.”

We thank Frida for telling us more about the important ways in which IFPA is working to improve the lives of people living with psoriatic disease. At ��ֳ� we are proud to be a long-term supporter of IFPA and remain committed to working with the advocacy community to better meet the evolving needs of patients. Together, we can make a difference.

solutions

World Psoriasis Day psoriasis IFPA

Comment:

Posted by Frida Dunger, 29 October 2021

Thank you for highlighting World Psoriasis Day and for prioritizing the patient voice in your work.

717 Likes

World Psoriasis Day 2021: Uniting for action

eCMSadmin — Fri, 29 Oct 2021 09:00:00 +0000

World Psoriasis Day 2021: Uniting for action

Jeron Evans, Patient Value Immunology & US Solutions

eCMSadmin Fri 29/10/2021 - 11:00

At ��ֳ�, everything we do starts with one simple question: “How will this create value for patients now and in the future?”

Why? Because we have a fundamental, continual commitment to enable patients, their caregivers, and their families to live their best lives. By focusing our immunology work on specific patient populations where we can make a meaningful difference, we move ever closer to achieving this.

Today, on World Psoriasis Day, we stand united with the International Federation of Psoriasis Associations (IFPA) to shine a light on the impact that psoriasis has on patients. Since 1971, IFPA has been effectively advocating for the psoriatic disease community and today its members represent over 60 million people living with psoriatic disease worldwide. IFPA aims to unite, strengthen and lead the global community to improve the lives of people affected by psoriatic disease.

Each year on October 29, World Psoriasis Day allows us to reflect on the important victories that have been achieved by IFPA and its supporters, whilst offering an opportunity to raise awareness of the many challenges and unmet needs still facing those living with psoriatic disease today.

We understand that psoriasis is more than just a skin disease. People with psoriasis can experience feelings of stigmatization, shame, embarrassment, anger and worry and frequently report difficulties at work and disrupted leisure activities. The social and emotional burdens of psoriasis, together with the visible symptoms, can significantly impact patients’ quality of life. By applying these important insights to inform our science, we can seek to deliver new options that can truly address patients’ needs and improve their quality of life.

At ��ֳ�, we are proud to be a long-term supporter of IFPA and of World Psoriasis Day, which this year follows the theme of ‘United’ – a theme that we are pleased to champion. We know that innovation cannot be delivered alone and recognize the importance of our collaborations with the dermatology community to better meet the evolving needs of patients. For this reason, we engage in partnerships with researchers, clinicians, and advocacy groups from around the globe. These partnerships also underpin our ongoing scientific and medical education programs in dermatology.

Today and every day, my ��ֳ� colleagues and I strive to advance science in immunology. By uniting to address patients’ unmet needs, support clinically meaningful research and build strong, collaborative advocacy partnerships, we can all help to make a meaningful difference for people living with psoriasis.

solutions

World Psoriasis Day Immunology IFPA

731 Likes

Understanding the impact of chronic inflammatory diseases on women: update on research with patients for patients

eCMSadmin — Wed, 30 Jun 2021 00:00:00 +0000

Understanding the impact of chronic inflammatory diseases on women: update on research with patients for patients

Iris Loew-Friedrich, Patient Value Development Solutions

eCMSadmin Wed 30/06/2021 - 02:00

At ��ֳ�, we have a fundamental commitment to enabling patients with severe diseases, their caregivers, and their families to live their best lives. It takes a deep understanding of the multifaceted impact of a disease to be able to develop medicines and solutions that will make a meaningful difference.

When assessing the impact of a disease, it’s too simplistic to look at patients as a collective. Severe chronic diseases will place different challenges on different people, at different times of their lives. There are also key gender disparities in the effects of some chronic conditions which shouldn’t be overlooked. For example, psoriasis and psoriasis arthritis - both chronic inflammatory diseases – cause women higher levels of stress, loneliness and unhappiness, compared to men.

��ֳ� has long been committed to understanding the unique needs of women with chronic inflammatory diseases and to improving their standard of care. Knowing the challenges they face, and gaps in their care that exist, is critical to strengthening our commitment.

Partnering with patients for patients

We’re grateful to have a long-standing partnership with the International Federation of Psoriasis Associations (IFPA) and the European Umbrella Organisation for Psoriasis Movements (EUROPSO).

Together we’re working to shine a light on the real impact of psoriasis and psoriatic arthritis on women. We’ve gathered insights from over 500 female patients from 11 different European countries. The findings show that these conditions cause significant impact on women’s wellbeing, careers and family life - knowledge we will use to shape our support services in the future. We look forward to publishing the full results of this ambitious project in the next couple of months.

For further information

Women living with a chronic inflammatory disease can get access to information and support at AdvantageHers.com*. Information on IFPA-member patient support groups around the world can be found here

*Advantage Hers is a global campaign designed to equip and empower women around the world living with chronic inflammatory diseases to take more active and informed roles in shared decision-making about their care

solutions

Patients Psoritatic Arthritis IFPA EUROPSO Advantage Hers

Comment:

Posted by Lorraine , 1 August 2021

Hi. Only just found this page. I Had to say you fill me with hope. As a patient I feel that pain for myself and others is taken a bit to lightly even with diagnosis.

710 Likes

IFPA

World Psoriasis Day 2023: Let’s Unite for Action

Leave a Comment

Advancing Innovation in Dermatology with Collaborative Partnerships

Leave a Comment

Uniting with the Community for World Psoriasis Day 2022

Leave a Comment

Together we can make a difference on World Psoriasis Day

Leave a Comment

World Psoriasis Day 2021: Uniting for action

Leave a Comment

Understanding the impact of chronic inflammatory diseases on women: update on research with patients for patients

Leave a Comment